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Background: Anaplastic thyroid carcinoma (ATC) is a rare and aggressive endocrine tumor with highly
undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in
ATC. The objectives of this study were (i) to characterize CSCs from ex vivo ATC specimens by investigating the
expression of several pluripotent stem cell markers, and (ii) to evaluate in vitro drug resistance modifications
after specific CSC transcription factor switch-off.
Methods: In ex vivo experiments, eight formalin-fixed, paraffin-embedded ATC specimens were analyzed by
reverse-transcription and real-time quantitative PCR and immunohistochemistry. In in vitro experiments using
ATC SW1736 cells, the expression levels of OCT-4, NANOG, and ABCG2 and the sensitivity to either cisplatin or
doxorubicin were evaluated after silencing.
Results: OCT-4,KLF4, and SOX2 transcription factors andC-KIT andTHY-1 stem surface antigens showedvariable
up-regulation in all ATC cases. The SW1736 cell line was characterized by a high percentage of stem population
(10.4– 2.1% of cells were aldehyde dehydrogenase positive) and high expression of several CSC markers (SOX2,
OCT4, NANOG, C-MYC, and SSEA4). SOX2 silencing down-regulated OCT-4, NANOG, and ABCG2. SOX2 si-
lencing sensitized SW1736 cells, causing a significant cell death increase (1.8-fold) in comparison to control cells
with 10lM cisplatin (93.9– 3.4% vs. 52.6– 9.4%, p < 0.01) and 2.7 fold with 0.5lM doxorubicin (45.8– 9.9% vs.
17.1– 3.4% p < 0.01).ABCG2 silencing caused increased cell death with both cisplatin (74.9– 1.4%) and doxorubicin
treatment (74.1– 0.1%) vs. no-target–treated cells (respectively, 45.8– 1.0% and 48.6– 1.0%, p < 0.001).
Conclusions: The characterization of CSCs in ATC through the analysis of multiple pluripotent stem cell markers
might be useful in identifying cells with a stem-like phenotype capable of resisting conventional chemotherapy. In
addition, our data demonstrate that SOX2 switch-off throughABCG2 transporter down-regulation has amajor role
in overcoming CSC chemotherapy resistance.
Introduction
Anaplastic thyroid carcinoma (ATC) is a rare, ag-gressive, and lethal endocrine cancer with morphologi-
cal features of an undifferentiated neoplasm. Around 50% of
patients have metastases at presentation, while another 25%
develop newmetastases soon after diagnosis. Due to the rapid
fatal course, surgery is rarely performed and generally only
for compressive symptoms. Radiotherapy and chemotherapy
are not fully effective, perhaps because they do not adequately
target the cancer-initiating cells (1).
Adult stem cells have been identified in normal human
thyroid glands (2). A link between stem and cancer cells has
been claimed for tumors supposedly deriving from immature
progenitors/stem cells or from formerly normal cells that
have acquired stem-like properties (3). So far, cancer stem
cells (CSCs) have been isolated based on the expression of
specific surface molecules (4–8), which have been associ-
ated with aggressive and metastatic behavior and not with
‘‘stemness’’ per se. Regarding ATC, it has been hypothesized
that the tumor initiates from the remnants of fetal thyroid
cells, rather than from adult thyrocytes undergoing a multi-
step carcinogenesis model (9). Unfortunately, the relative
rarity and rapidly fatal nature of ATC has limited functional
studies on ex vivo tissues. Here we describe the expression of a
panel of CSC markers in ATC specimens and in ATC cell line
SW1736, a well-validated ATC cell line (10), by analyzing
surface and nuclear transcription factors, the latter implicated
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in self-renewal and maintenance of CSC pluripotency, as well
as aldehyde dehydrogenase activity (ALDH) (11). Moreover,
the role of these markers in drug sensitivity was assessed in
the SW1736 cell line.
Methods
Specimens
This studywas approved by the Institutional Review Board
at the Faculty of Medicine of the University of Palermo. At the
time of surgery, all patients signed an informed consent for
the scientific use of their data (12).
Eight archival formalin-fixed, paraffin-embedded ATC
tissue specimens were used for this study. Diagnosis of ATC
was performed by two independent pathologists according to
the current classification (13). Normal thyroid tissues from
12 cases contralateral to the lobe with papillary thyroid tumor
(less than 1 cm) were used as control samples.
Immunohistochemistry
Five-micrometer sections were analyzed for the expression
of SSEA4 and SOX2. Briefly, for SSEA4, tissue sections were
deparaffinized, rehydrated, and microwave-heated in 10mM
sodium citrate buffer for antigen retrieval. Sections were then
incubated with 3% hydrogen peroxide in phosphate-buffered
saline (PBS) for 5 minutes, and blocked with 3% bovine serum
albumin (BSA) in PBS. Incubationwithmouse andmouse anti-
human SSEA4 (IgG3, clone 813-70, Santa Cruz Biotechnology,
Santa Cruz, CA) was performed at room temperature for
1 hour. Expression was detected with secondary biotinylated
antibodies, streptavidin/horseradish peroxidase and chro-
mogen 3-amino-9-ethylcarbazole substrate. For SOX2, the
semi-automated Ventana system was used according to the
manufacturer’s instructions (BenchMark XT, Ventana Medical
Systems, Inc., Tucson, AZ), antigens were unmasked in CC1
(Ventana Medical Systems, Inc.) for 90 minutes, and sections
were incubated with rabbit antihuman SOX2 (Poly6308, Bio-
Legend, San Diego, CA) at 37C for 1 hour. Expression was
detected with the DAB ultraView Universal detection kit
(Ventana Medical Systems, Inc.). Slides were counterstained
with hematoxylin and eosin and blueing reagent according to
the manufacturer’s instructions. The number of SSEA4+ and
SOX2+ cells was assessed in light microscopy. For each case, a
minimum of 103 cells was counted in three randomly collected
sections, and the percentage of positive cells was regarded as
the labeling index (LI).
Reverse-transcription PCR and real-time
quantitative PCR
Total RNA was extracted from 10 lm sections using
High Pure RNA Paraffin Kit (Roche Diagnostics GmbH,
Mannheim, Germany) or from cultured SW1736 cells using
the RNeasy Mini Kit (Qiagen, Milan, Italy), including a
digestion step with DNase I. RNA quantity and quality
were assessed by UV spectrophotometry. The RNA ex-
tracted was reverse-transcribed with Random Hexamers
(Applied Biosystems, Darmstadt, Germany) and Improm II
Reverse Transcriptase (Promega Italia, Milan, Italy), accord-
ing to the manufacturer’s protocol. Thyroglobulin (TG),
thyroperoxidase (TPO), sodium/iodide symporter (NIS), and
oncofetal fibronectin (onfFN) were analyzed with reverse-
transcription (RT)-PCR as previously described (14). Briefly,
primer pair sequences, cDNA fragment sizes and annealing
temperatures were as follows: TG (762 bp), 5¢-CTT CGA GTA
CCA GGT TGA TGC C-3¢ and 5¢-GGT GGT TTC AGT GAA
GGT GGA A-3¢ (55C); TPO (593 bp), 5¢-TGT GTC CAA CGT
GTT CTC CAC AG-3¢ and 5¢-AAG ACG TGG CTG TTC TCC
CAC-3¢ (55C); NIS (179 bp), 5¢-CTA TGG CCT CAA GTT
CCT CT-3¢ and 5¢-TCG TGG CTA CAA TGT ACT GC-3¢
(57C); and onfFN (215 bp), 5¢-TCT TCA TGG ACC AGA
GAT CT-3¢ and 5¢-TAT GGT CTT GGC TAT GCC T-3¢ (55C).
KLF4, SOX2, OCT-4, C-MYC, C-KIT, THY-1, PAX-8, ABCG2,
and TTF-1 expression was analyzed by real-time quantitative
PCR (qRT-PCR) using Quantitect SYBR Green PCR kit (Qia-
gen, Milan, Italy). PCR primers and probes were also pur-
chased from Qiagen. All reactions were performed using a
LightCycler 1.5 Instrument (Roche Diagnostics GmbH). Gene
expression was normalized against the housekeeping gene
b-actin, which was stable among all the samples (For: 5¢-GGA
CTTCGAGCAAGAGATGG-3¢, and Rev: 5¢-AGCACTGTG
TTG GCG TAC AG-3¢).
Cell cultures
The SW1736 cell line was cultured in Dulbecco’s modified
Eagle’smediumhigh glucosemedium supplementedwith 10%
fetal bovine serum and 5% glutamine. Cultures were main-
tained in 5% carbon dioxide at 37C in a humidified incubator.
Immunocytochemistry
SW1736 cells were plated in chamber slides (Lab-Tek,
Nunc, Inc., Naperville, IL), allowed to attach for 24 hours and
then used for immunocytochemistry. Cells were fixed in 2%
paraformaldehyde in PBS for 20 minutes at room tempera-
ture, then washed twice in PBS, blocked with 5% BSA and
permeabilized for 10 minutes at room temperature with a
blocking solution containing 0.1% saponin. Cells were incu-
bated with rabbit anti-human SOX2 (Poly6308, BioLegend,
San Diego, CA) and/or mouse anti-human SSEA4 (IgG3,
clone 813-70, Santa Cruz Biotechnology) in blocking solution
containing saponin overnight at 4C and subsequently rinsed
again with blocking solution plus saponin. The secondary
antibodies used were AF594 goat anti-rabbit IgG, AF488 goat
anti-mouse IgG3 (Invitrogen, Carlsbad, CA). Cells were
counterstained with 4¢,6-diamidino-2-phenylindole (DAPI)
0.5 lg/mL (Sigma-Aldrich, St. Louis, MO).
Flow cytometry
The identification of ALDH + cells was performed using the
ALDEFLUORkit (StemCell Technologies, VodenMilan, Italy).
In accordance with manufacturing procedures, as a negative
control, an aliquot of cells from each sample was treated with
50mmol/L of diethylaminobenzaldehyde, a specific ALDH in-
hibitor, and intracellular fluorescent product was measured by
flow cytometry (FACSCalibur, BectonDickinson, San Jose, CA).
Confocal and two-photon microscopy
Fluorescence imageswere acquired in 1024· 1024 format in
three channels by means of a Leica TCS SP5 inverted Laser
Scanning Confocal Microscope using an HCX PL APO CS
63.0 · 1 oil objective NA = 1.4 (Leica Microsystems, Leica,
Wetzlar, Germany); the pinhole size was 80 lm. Images were
sequentially acquired using a scanning frequency of 400Hz.
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Alexa 488 dye was excited using the 488 nm line of an
Argon laser and fluorescence signal was acquired in the range
500–550 nm (green channel). DAPI and Alexa 594 dye were
excited using a pulsed infrared laser source: ‘‘Mai Tai’’
(Spectra-Physics Santa Clara, CA) tuned at 760 nm with two-
photon excitation. The emission spectral ranges were set to
390–460 nm for DAPI (blue channel) and 600–670 nm for
Alexa 594 (red channel).
siRNA transfection
siRNAs transfection in SW1736 cells was performed using
INTERFERinTM transfection agent (Polyplus-Transfection,
Illkirch, France), according to the manufacturer’s instructions.
Briefly, cells were seeded into six-well plates at a density of
250,000 cells/well or 96-well plates at a density of 3000 cells/
well. The transfection agent and the siRNA complex were
added to the cells and incubated for 72 hours for mRNA
analysis and 96 hours for protein detection. The final con-
centration of SOX2 siRNA was 100 nM for mRNA analysis
and 150 nM for protein detection and 40 nM for OCT-4 and
ABCG2 siRNA. Each assay was performed in triplicate in at
least three independent experiments. SOX2 was silenced
using Stealth SiRNA SOX2 HSS144045 (Invitrogen, Milan,
Italy). siCONTROL Stealth siRNANegative Control was used
as a control (Invitrogen, Milan). OCT-4 and ABCG2 were
silenced by Oct-3/4 and ABCG2 siRNA (h) (Santa Cruz Bio-
technology), and control siRNAs were used as a no-target
control (Santa Cruz Biotechnology).
Cytotoxicity
SW1736 cells were plated in 96-well plates in a 100lL
medium/well containing 100 nM of SOX2 siRNA or ABCG2
siRNA (h) or siCONTROL or 0.5 lL of INTERFERinTM alone.
After 24 hours the medium was refreshed and the cells were
cultured with 0.5, 1.5, or 10lM cisplatin (Pharma, Leobendorf
Kundl, Austria) or 0.5, 1, or 1.5lMdoxorubicin (Ebewe Pharma,
Leobendorf Kundl, Austria) up to 48 hours. Cell proliferation
wasassessedbya colorimetric assayusing3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich). Absorbance was read at 550 nm in a MultiskanFC
microplate reader (Thermo Fisher Scientific, Milan, Italy).
Protein extraction and Western blot analysis
Proteins were extracted from cultured cells using Radio-
ImmunoPrecipitation Assay (RIPA) buffer (50mM Tris-HCl,
pH 7.4, 150mMNaCl, 1% Nonidet P40), supplemented with a
protease inhibitor cocktail (Complete mini, Roche Diagnostics
GmbH) and phosphatase inhibitors. Protein content was de-
termined according to Bradford’s method. Proteins were
separated by NuPAGE 4-12% Bis-Tris Gel (Invitrogen,
Milan), electrotransferred to nitrocellulose membrane, and
blotted with the following primary antibodies: rabbit antihu-
man SOX2 (Poly6308, BioLegend, San Diego, CA), mouse an-
tihuman Oct-4 (sc-5279, Santa Cruz Biotechnology), goat
antihuman Nanog (sc-30331, Santa Cruz Biotechnology),
mouse antihuman ABCG2 (sc-58222 Santa Cruz Biotechnol-
ogy), rabbit antihuman Akt1/2/3 (sc-8312 Santa Cruz Bio-
technology), rabbit antihuman p-Akt1/2/3 (sc-293095 Santa
Cruz Biotechnology), and mouse anti b-actin IgG1 (A5441,
Sigma-Aldrich). Secondary antibodies were goat anti-rabbit
IgG-HRP (sc-2030, Santa Cruz Biotechnology), goat anti-
mouse IgG-HRP (sc-2031, Santa Cruz Biotechnology), and
donkey anti-goat IgG-HRP (sc-2033, Santa Cruz Biotechnol-
ogy). Antigen–antibody complexes were visualized using the
SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific) on a CCD camera (Chemidoc, Bio-
Rad, Milan, Italy). Western blot bands were quantified with
ImageJ software (National Institutes of Health, Bethesda, MD).
Statistical analysis
Statistical analysis (t-test, two-tailed, with confidence in-
terval at 95%) was performed with GraphPad Prism 5 soft-
ware for Windows (GraphPad Software, Inc., La Jolla, CA).
Results
ATC is a highly undifferentiated tumor
RT and qRT-PCR analysis were performed for mature and
fetal thyrocyte markers. Expression of TG, TPO, and NIS was
never detected, indicating the undifferentiated status of ATC
specimens. By contrast, onfFN, PAX-8, and TTF-1 were posi-
tive in all eight cases, proving the thyroid origin of the tumors
(Fig. 1A–C).
FIG. 1. RT-PCR (A) and qRT-PCR (B, C) analysis for mature and fetal thyrocyte markers. Absence of TG, TPO, and NIS
confirms the undifferentiated status of ATC specimens (A: lanes 1–8, ATC; lane 9, normal thyroid; 10, negative control).
Expression of onfFN, PAX-8, and TTF-1 proves the thyroidal origin of the tumors (B, C). Values are shown as mean – SE. ATC,
anaplastic thyroid carcinoma; bp, base pairs; RT-PCR, reverse-transcription PCR; qRT-PCR, real-time quantitative PCR; TG,
thyroglobulin; TPO, thyroperoxidase; NIS, sodium/iodide symporter.
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Identification of cancer and pluripotent stem cell
markers in ATCs
All cases showed very variable hyperexpression of various
stem cell markers in comparison with normal thyroid cells
(see Methods) used for normalization. Nuclear (SOX2, OCT4,
KLF4, and C-MYC) and surface (THY-1 and C-KIT) stem
markers were evaluated by qRT-PCR (Fig. 2A–F) and SSEA4
by immunohistochemistry (LI comprised between 35.8 – 3.3%
and 5.5 – 1.1%; Fig. 3B).
SW1736 characterization and ‘‘stemness’’
The undifferentiated status of ATC cell line SW1736 was
confirmed by PCR by the presence of onfFN and the absence of
the thyrocyte-specific differentiating markers TG, TPO, and
NIS (Fig. 4A). The constitutive activation of p-AKT was
shown by Western blot analysis (Fig. 4B). The existence of
stem cell population in this cell line was demonstrated by the
higher expression of nuclear stem markers SOX2, OCT-4,
NANOG, and C-MYC in SW1736 in comparison with normal
FIG. 2. Expression of pluripotent stem cell nuclear transcription factors and surface stem cell markers in ATC. qRT-PCR
analysis of nuclear stem cell transcription factors (A–D) and surface stem cell markers (E–F). Values were normalized to
normal thyroid (see Methods) and shown as mean – SE. Data are representative of three independent experiments.
FIG. 3. Co-localization of
SOX2 and SSEA4. (A) Con-
focal analysis: surface stem
cell marker SSEA4 (green)





For image acquisition and
magnification see methods.
(B) Immunohistochemistry:
SSEA4 and SOX2 were
strongly positive in the same
four cases (20· magnifica-
tion).
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thyroid cells (Fig. 4C) and by the identification of a high
percentage (10.4 – 2.1%) of ALDH + cells (Fig. 4D). Interest-
ingly, our confocal analysis showed co-localization of the
stem cell markers SSEA4 and SOX2 (Fig. 3A). Our in vitro
findings are in agreement with what we found in human
tumor specimens, in which 50% of the tumors analyzed
(ATC1, 2, 3, 4) overexpressed both SSEA4 and SOX2 (Fig. 3B).
SOX2 expression and silencing in SW1736 cell line
In SW1736 cell lines, SOX2 was more highly expressed
compared with both OCT-4 and the downstream gene NA-
NOG (Fig. 5A). Thus, to establish the relationship between
SOX2, OCT-4, NANOG, and ABCG2, we evaluated their ex-
pression after SOX2 silencing. As expected, SOX2 silencing
(1.76 – 0.03 vs. 0.60 – 0.01, p < 0.0001, optical density [OD]
42.45 vs. 18.62) caused down-regulation of the downstream
genes NANOG (0.55 – 0.07 vs. 0.07 – 0.02, p < 0.01; OD 24.5 vs.
4.2) and ABCG2 (4.99 – 0.03 vs. 1.09 – 0.17 p < 0.0001, OD 39.8
vs. 13.8), but also caused a decrease in OCT-4 expression
(2.55 – 0.19 vs. 0.83 – 0.03 p < 0.001, OD 26.2 vs. 1.3) (Fig. 5B–
G). By contrast, OCT-4 silencing (0.87 – 0.02 vs. 0.38 – 0.05
p < 0.0001) showed no effect on SOX2 expression (Fig. 5H, I).
SOX2 switch-off effect on cisplatin
and doxorubicin treatment
SOX2 is involved in mediating regulation on SW1736 re-
sistance to cisplatin (median inhibition concentration [IC50]
10.9 – 2.5 lM at 48 hours) and doxorubicin (IC50 4.9 – 2.0 lM
at 48 hours) in SW1736 cells. The MTT assay showed that
SOX2 silencing caused chemosensitization in siRNA-treated
cells compared to no-target–treated cells. Treatment with 1.5
or 10 lM cisplatin caused 59.3 – 1.2% and 93.9 – 3.4% of cell
death, respectively, in SOX2 siRNA-treated cells vs.
44.9 – 2.3% ( p < 0.001) and 52.6 – 9.4% ( p< 0.01) in no-target–
treated cells. Doxorubicin treatment at 0.5 or 1lM caused
45.8 – 9.9% and 51.2 – 2.5% of cell death in silenced cells vs.
17.1 – 3.4% ( p< 0.01) and 35.7 – 9.9% ( p < 0.05) in unsilenced
cells (Fig. 6A).
ABCG2 switch-off effect on cisplatin
and doxorubicin treatment
To investigate the mechanism whereby SOX2 silencing
causes cisplatin and doxorubicin chemosensitization, we an-
alyzed the effect of the drug on ABCG2. The silencing of
ABCG2 (66.2 – 3.1%, p < 0.001, data not shown) was associated
with a sensitization to cisplatin and doxorubicin. The MTT
assay showed that treatment with 0.5, 1.5, or 10 lM cisplatin,
respectively, caused 59.2 – 1.1%, 61.2 – 0.6%, and 74.9 – 1.4%
of cell death in ABCG2 siRNA-treated cells vs. 28.5 – 4.0%,
44.8 – 1.6%, and 45.8 – 1.0% ( p< 0.001) in no-target–treated
cells. Doxorubicin treatment at 0.5, 1.0, and 1.5 lM, respec-
tively, caused 15.9 – 1.4%, 44.0 – 0.3%, and 74.1 – 0.1% of cell
death in silenced cells vs. 4.2 – 0.1%, 24.4 – 2.6%, and
48.6 – 1.0% in unsilenced cells ( p< 0.001; Fig. 6B).
FIG. 4. (A) SW1736 cell line characterization. RT-PCR analysis of thyrocyte markers in SW1736 cells. Lane 1, normal
thyroid; lane 2, SW1736 cell line; lane 3, negative control; bp, base pairs. (B) Western blot analysis of AKT and p-AKT. (C)
qRT-PCR analysis of relative expression of SOX2, OCT-4, NANOG, and C-MYC in the SW1736 cell line (,) vs. normal
thyroid (-). Data are representative of three independent experiments. Values are shown as mean– SE. **p< 0.001,
***p < 0.0001. (D) FACS analysis of SW1736 cells using ALDEFLUOR assay. Thyroid cancer cells exposed to ALDEFLUOR
substrate and a specific inhibitor of aldehyde dehydrogenase (ALDH) (i)were used to define the population with high ALDH
activity (ii). SSC-H, side light scatter; FL1-H, fluorescence channel.
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Discussion
The existence of CSCs may account for the high degree of
dedifferentiation, sustained proliferation, and resistance to
chemotherapy of ATC lesions (9,14). It has been demon-
strated that murine and human somatic cells can be induced
into pluripotent stem cells with a combination of four defined
transcription factors (OCT-4/NANOG plus either C-MYC/
KLF4 or SOX2/LIN28) (14,15). Indeed, these transcription
factors play a pivotal role in the maintenance of pluripotency
and self-renewal of embryonic stem cells and could therefore
be responsible for sustained growth of ATC. Interestingly, in
all eight specimens obtained from the archives of the Pathol-
ogy Department at the University of Palermo, we found
variable expression of stem nuclear transcription markers
SOX2, OCT-4, C-MYC, and KLF4. In addition, all ATCs also
showed up-regulation of the stem cell–related surface mark-
ers C-KIT and THY-1, which have also been described in
several other tumors (16–19) and SSEA4 expression, a human
embryonic surface stem cell marker, which has been proposed
for the identification of CSCs in undifferentiated tumors (20).
Though the low number of ATC tissues used cannot provide a
definitive result, the findings of this study may indicate that
cells with a pluripotent phenotype exist within the tumor,
consistent with the CSC hypothesis, but with very marked
variability in stemmarker expression, suggesting the need for
a panel ofmarkers and the invalidity of a singlemarker. In our
ATC cases, indeed, CD133 was only overexpressed in four
cases and LIN28 and NANOG were never detected, while in
the SW1736 cell line, NANOG was strongly expressed and C-
KIT, THY-1, CD133, LIN28, and KLF4were not detected (data
not shown). It is noteworthy that SOX2 and SSEA4 were
FIG. 5. Analysis of SOX2 silencing. qRT-PCR analysis in the SW1736 cell line (A); SOX2 (B), NANOG (C), ABCG2 (D), and
OCT-4 (E) expression in the SW1736 cell line after SOX2 silencing with stealth siRNA (siSOX2) vs. siCONTROL treated cells
(Control). Western blot (F, G) of SOX2, OCT-4, and NANOG with proteins extracted from SW1736 cells after SOX2 silencing
with stealth siRNA (,) vs. siCONTROL treated cells (-). Analysis of OCT4 silencing: OCT4 (H) and SOX2 (I) expression in
the SW1736 cell line after OCT-4 silencing with siRNA (siOCT-4) vs. siCONTROL treated cells (Control). Data are repre-
sentative of three independent experiments. Values are shown as mean– SE. *p < 0.05, **p < 0.01, ***p < 0.001,****p< 0.0001.
OD, optical density.
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simultaneously overexpressed in the same ex vivo ATC cases
(ATC1, 2, 3, 4) and were found to be co-localized in the
SW1736 cell line.
Recent studies have shown a central role of SOX2 in stem
cell behavior (21,22). In particular, in malignant glioblastoma,
SOX2 proved to be amplified or overexpressed, and ectopic
SOX2 expression was not only sufficient to induce invasion
and migration of glioma cells, but was also essential for
maintaining these properties (21). This gene has been de-
scribed as being involved in sustaining self-renewal of several
stem cells, in particular neural stem cells (22). Moreover,
silencing of SOX2 in freshly derived glioblastoma tumor-
initiating cells stopped proliferation and caused lack of tu-
morigenicity in immunodeficient mice. Consequently, SOX2
or its immediate downstream effectors have been considered
an ideal target for glioblastoma therapy (22). Recent studies
have shown that SOX2 overexpression occurs in several other
human malignant tumors; for example, in 43% of basal cell-
like breast carcinomas and 41% of small cell lung cancers
(23,24). The relationship between aberrant expression of
SOX2, OCT-4, and NANOG in cancer has been studied in
various cancers (25–27). Moreover Masui et al. (25) showed
that SOX2 is indispensable for maintaining embryonic stem
cell pluripotency. Thus, in embryonic stem cells the expres-
sion of most pluripotency-associated genes, including
NANOG, is regulated by an enhancer containing OCT-4 and
SOX2 bindingmotifs (28). In this study we showed that SOX2
was overexpressed not only in ATC specimens in comparison
with normal thyroid, but also in the SW1736 cell line, where it
plays a pivotal role. Indeed, in this model SOX2 was ex-
pressed more abundantly than both stem nuclear transcrip-
tion factors OCT-4 and NANOG. Moreover, SOX2 silencing
by RNA interference (siRNA) caused down-regulation not
only of the downstream NANOG gene but also of OCT-4,
confirming that SOX2 is able to regulate OCT-4 (27,29). In
addition, SOX2 down-regulation caused chemosensitization
to cisplatin and doxorubicin. Our findings suggest that this
chemosensitization could depend on down-regulation of
ABCG2, which was strongly down-regulated after SOX2 si-
lencing. Indeed, both chemotherapeutic agents are ABCG2
substrates (30,31), and Zheng and co-workers (32) showed
that ABCG2 has a major responsibility for side population
(stem cell–like subpopulation) resistance to doxorubicin in
ATC treatment. Hence, our data strongly support a hierar-
chical model in which SOX2 plays a central role. In this con-
nection, SOX2 is able to down-regulate OCT-4, but not vice
versa. Moreover, several recent studies have shown that an
important relationship exists between AKT pathway activa-
tion and SOX2, OCT-4, NANOG, and self-renewal capacity
(33,34). In our study, SW1736 showed a constitutive expres-
sion of p-AKT, confirming the relationship between AKT and
the self-renewal–related markers SOX2 and OCT4.
So far, we have confirmed the existence of CSCs in ATC
tissues (9,14), showing that several stem cell markers are ex-
pressed in ATC specimens and in the SW1736 cell line, sug-
gesting that a single marker cannot exclusively identify CSCs,
and a pool of candidate antigens must be considered. No-
tably, both pluripotent nuclear transcription factors and sur-
face antigens were mainly up-regulated in the same ATC
cases and in SW1736 cell lines inwhich anALDH + population
was also found. Analogous to other markers, ALDH activity
is not a stem marker associated with a negative prognosis in
all cancer types. Indeed, in malignant melanoma it seems not
to correlate with ‘‘stemness’’ (35), and its role has also been
challenged in ovarian cancer (36–38). On the other hand, an
ALDH1 activity increase has been associated with undiffer-
entiated cells in numerous tissues, such as ovarian, breast,
pancreatic, multiple myeloma, acute myeloid leukemia, and
lung (37–43), and particularly in the human ATC-8505C cell
line (44).
Taken together, these data further support the necessity of a
panel of markers for identifying CSCs. In particular, SOX2
appears to play a pivotal role in the resistance of ATC to
chemotherapy by regulating ABCG2 transporter gene expres-
sion, which is responsible for the efflux of drugs. In conclu-
sion, the present work supports a hierarchical model
FIG. 6. Effects of SOX2




(MTT) analysis after cisplatin
(i) and doxorubicin (ii) treat-
ment of SW1736 cells after
SOX2 (A) or ABCG2 (B) si-
lencing with stealth siRNA
(siRNA, ) vs. siCONTROL
treated cells (Control, -).
Data are representative of
three independent experi-
ments. Values are shown as
mean– SE. *p< 0.05, **p< 0.01,
***p< 0.001.
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controlled by SOX2 in ATC and opens the way to finding new
therapeutic strategies based on switching off SOX2 in order to
further understand the potential involvement of CSCs in
ATC.
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